Sai Life Sciences Ltd Q4 FY26 Earnings Analysis

- Sai Life Sciences expects to sustain healthy revenue growth driven by a robust commercial pipeline and strong demand. - The company foresees 15% to 20% revenue CAGR over a three-year period, with some years possibly outperforming this range. - New capacity expansions, including a new mixed-use facility near Hyderabad (non-GMP, peptide, and GMP capacity), are planned to support growth. - Current capacity utilization is around 60%, leaving headroom for near-term growth without immediate incremental capacity. - Growth will be bolstered by both development and commercial contracts, with diversification across multiple molecules and modalities. - Visibility from customer discussions indicates ongoing active engagements and pipeline progress feeding future capacity requirements. - Margins are expected to be sustained at 28%-30%, balancing growth investments and operational efficiencies. - Tactical supply chain shifts, including customers diversifying sourcing from China to India, provide incremental opportunities.

- Sai Life Sciences has demonstrated strong growth with Q3 FY ‘26 revenue up 27% YoY and EBITDA margin expanding to around 34%. - Nine-month FY ‘26 revenue grew 43% YoY with EBITDA margin improving to 30%, ahead of the 28%-30% target. - Management expects to sustain EBITDA margins in the 28%-30% range while maximizing growth. - Capital expenditure is aligned with long-term demand, with capacity utilization at ~60%, indicating room for growth. - Growth guidance over the next 3 years is a broad-based revenue CAGR of 15%-20%. - Management is confident about maintaining positive growth momentum driven by strong demand, operating leverage, and strategic investments. - No specific EPS guidance provided, but strong PAT growth with 86% YoY increase in Q3 and 199% in nine months indicates profitability improvements. - Investments in technology and capacity expansions to support future revenue and margin growth.

- Adding 450 KL manufacturing capacity in FY’27, increasing capacity by ~70%. - Starting expansion of a new mixed-use site in Hyderabad, expected to be operational within 18-24 months; will include non-GMP, peptide, and GMP capacities. - Animal health Phase I expansion targeted for completion by March ’27, enabling validation and commercialization of veterinary API products; current investment less than INR 50 crores with an additional INR 70-75 crores planned for next phase. - Ongoing R&D expansions: - First phase at Hyderabad Unit 8 commissioning in Q4 FY’26 with ~200 fume hoods. - New process facility R&D building commissioning by Sept ’26, doubling process R&D capacity. - Peptide process development and pilot facility targeted for Sept ’26. - OEB laboratories for ADC capabilities completion by Oct ’26. - Focus on technology-first approach for capacity addition to remain best-in-class long-term. - Investments guided by customer visibility and strategic growth priorities.

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The management discusses capital expenditure plans and capacity expansions funded through internal means. - They emphasize maintaining financial discipline in operating and capital expenditures. - No references to new fundraising rounds or debt/equity issuance are made during the Q&A or closing remarks. - If investors have specific questions on this topic, they are encouraged to reach out via investorrelations@sailife.com for detailed clarifications.

The transcript does not explicitly mention current or expected order book or pending orders in numeric detail. However, relevant insights include: - Capacity expansions are in progress based on "relative visibility" from ongoing customer conversations, indicating a healthy pipeline and expected demand. - The company is adding 450 KL capacity in FY’27 and is starting a new mixed-use facility near Hyderabad (non-GMP, peptide, and GMP capacity) with a 18-24 month timeline. - Expansion decisions are balanced against customer visibility, with cautious but forward-looking capex aligned with active pipeline products, mostly in Phase 2 moving to Phase 3. - The management refers to "fair number of strategic conversations" with customers reflecting strong demand outlook. - The commercial pipeline includes two launched products, seven late-stage molecules added this year, and several products still in clinical stages. - Long-term growth and capacity plans suggest a positive and expanding order book but no exact order book values disclosed.